Koninklijke DSM N.V.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Dimitri de Vreeze
- Full Time Employees
- 21,760
- Sector
- Basic Materials
- Industry
- Chemicals - Specialty
- Address
- Het Overloon 1 Heerlen Netherlands 6411 TE
- IPO Date
- Jul 16, 2001
- CIK
- 0001339422
- Website
- dsm.com
- Similar Companies
- Business
- Koninklijke DSM N.V. (RDSMY), now operating as dsm-firmenich following its May 2023 merger of equals with Swiss fragrance and flavor company Firmenich, focuses on nutrition, health, and beauty solutions; it provides innovative ingredients and services across perfumery and beauty, taste texture and health, health nutrition and care, and animal nutrition and health segments. The company offers a broad portfolio of products including vitamins from A to Z, carotenoids, nutritional lipids, minerals, enzymes, eubiotics, probiotics, prebiotics, human milk oligosaccharides, savory flavors, hydrocolloids, yeast extracts, cultures, and biotech-derived ingredients for human and animal nutrition, early life nutrition, dietary supplements, pharmaceuticals, medical nutrition, personal care, food and beverage applications such as dairy baking beverages savory and plant-based alternatives, and pet food; it also delivers fragrance solutions, premium scents, botanical nutraceuticals, active pharmaceutical ingredients, premixes, market-ready and personalized nutrition solutions, and expert services in regulatory affairs and formulation. Founded in 1902 and headquartered in Heerlen, Netherlands, with dual operations alongside Kaiseraugst, Switzerland, dsm-firmenich employs over 28,000 people across approximately 330 sites in nearly 60 countries, serving global markets in Europe, North America, Latin America, Asia, the Middle East, and Africa. Recent developments include the completion in June 2025 of its EUR1.5 billion sale of the stake in the Feed Enzymes Alliance to Novonesis, enabling a long-term commercial relationship for enzyme resale through its animal nutrition premix network; an increase in its share repurchase program to EUR1.08 billion effective June 2025 to reduce issued capital, following the enzymes deal; the August 2024 conclusion of a new EUR1.8 billion revolving credit facility replacing prior arrangements; and the ongoing separation of its Animal Nutrition & Health business announced in 2024, alongside 2024 financials showing EUR12.8 billion in sales from continuing operations up 4% pro forma and adjusted EBITDA of EUR2.1 billion up 19% pro forma.
Koninklijke DSM (OTCMKTS:RDSMY) Stock Price Passes Above Fifty Day Moving Average – Time to Sell?
Royal DSM: Quality At A Price
Koninklijke DSM N.V. (RDSMY) CEO Geraldine Matchett on Q2 2022 Results - Earnings Call Transcript
UNVR or RDSMY: Which Is the Better Value Stock Right Now?
UNVR vs. RDSMY: Which Stock Should Value Investors Buy Now?
DOW or RDSMY: Which Is the Better Value Stock Right Now?
DOW or RDSMY: Which Is the Better Value Stock Right Now?
DOW vs. RDSMY: Which Stock Is the Better Value Option?
5 Great Green Stocks Making a Direct Impact
Koninklijke DSM N.V. (RDSMY) on Q4 and FY 2021 Results - Earnings Call Transcript
BASFY vs. RDSMY: Which Stock Is the Better Value Option?
UNVR vs. RDSMY: Which Stock Is the Better Value Option?
OLN vs. RDSMY: Which Stock Should Value Investors Buy Now?
OLN or RDSMY: Which Is the Better Value Stock Right Now?
OLN or RDSMY: Which Is the Better Value Stock Right Now?
AVNT or RDSMY: Which Is the Better Value Stock Right Now?
BASFY or RDSMY: Which Is the Better Value Stock Right Now?
JTD: Multi-Asset Fund Set To Get Larger, Some Appeal Here
EMN vs. RDSMY: Which Stock Should Value Investors Buy Now?
HUN vs. RDSMY: Which Stock Should Value Investors Buy Now?